Inscripta has developed a gene-editing technology that provides scalable digital genome engineering with unparalleled simplicity. Their technology creates cost-effective libraries of thousands of bespoke protein, pathway, or genome variants, each with specific and trackable mutations. This empowers researchers to design, engineer, assess, and monitor results effectively and efficiently.
GoldenArc, Vertical Venture Partners, iGlobe Partners, Spruceview Capital Partners, OMX Ventures, D1 Capital Partners, Foresite Capital Management, Fidelity Management & Research, Morgan Stanley, Oak HC/FT, Korys Investments, Venrock, ND Capital, Spruce Capital Partners, Phoenix International Investments, Durable Capital Partners, Counterpoint Global, JS Capital Management, Jonathan Feldstein, Paladin Capital Group, T. Rowe Price.